Der Internist

, Volume 54, Issue 4, pp 449–463

Antizytokintherapie

CME Zertifizierte Fortbildung

Zusammenfassung

Zytokininhibitoren haben die Behandlung chronisch-entzündlicher Erkrankungen revolutioniert, insbesondere die Therapie von Autoimmunerkrankungen. Dabei nimmt die Tumor-Nekrose-Faktor(TNF)-α-Blockade weiterhin eine zentrale Stellung ein. Mittlerweile stehen 5 TNF-Antagonisten mit Indikationen in der Rheumatologie, Dermatologie und Gastroenterologie zur Verfügung. Weitere Therapieansätze kamen in den letzten 10 Jahren hinzu, z. B. die Blockade von Interleukin(IL)-1, IL-6 und IL-12/23. Der große Vorteil der Zytokinblockade ist ihr schneller Wirkungseintritt und spezifischer Wirkansatz verbunden mit einem tolerablen Nebenwirkungsprofil. Dennoch können teils schwere Nebenwirkungen auftreten, v. a. die Tuberkulose- und Hepatitis-B-Infektion bzw. -Reaktivierung. Ein entsprechendes Screening vor der Therapie ist daher Standard. Ebenso ist eine gute Dokumentation des Krankheitsverlaufs von Bedeutung. Die Entwicklung weiterer Behandlungsansätze zur Remissionsinduktion und -erhaltung bleibt unerlässlich.

Schlüsselwörter

Zytokininhibitoren Antikörper Interleukin-1 Tumor-Nekrose-Faktor α Interleukin-6 

Anticytokine therapy

Abstract

Anticytokine therapies have revolutionized the treatment of chronic inflammatory diseases, particularly autoimmune diseases such as rheumatoid arthritis. As the first introduced principle of cytokine blockade in the 1990s, tumor necrosis factor (TNF)-α antagonists still represent the leading anticytokine therapy. There are currently five TNF antagonists available with indications in the fields of rheumatology, dermatology, and gastroenterology. Other therapeutic approaches have been introduced in the last 10 years, e.g., the blockade of interleukin (IL)-1, IL-6, and IL-12/23. The advantages of cytokine blockers are their rapid onset of action with high response rates and a tolerable safety profile. Nevertheless, anticytokine therapy can cause increased rates of tuberculosis and hepatitis B infections or reactivation. An appropriate screening before therapy is mandatory, and thorough monitoring of the disease course before and during therapy is also important. The development of further anticytokine drugs for the induction and maintenance of remission is, therefore, required.

Keywords

Cytokine inhibitors Antibodies Interleukin-1 Tumor necrosis factor-alpha Interleukin-6 

Literatur

  1. 1.
    Beutler B, Greenwald D, Hulmes JD et al (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552–554PubMedCrossRefGoogle Scholar
  2. 2.
    Dinarello CA, Cannon JG, Wolff SM et al (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433–1450Google Scholar
  3. 3.
    Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110PubMedCrossRefGoogle Scholar
  4. 4.
    Furst DE, Wallis R, Broder M et al (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36:159–167PubMedCrossRefGoogle Scholar
  5. 5.
    Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884–1894PubMedCrossRefGoogle Scholar
  6. 6.
    Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531–545PubMedCrossRefGoogle Scholar
  7. 7.
    Lipsky PE, Heijde DM van der, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602Google Scholar
  8. 8.
    Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259Google Scholar
  9. 9.
    Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–1411PubMedCrossRefGoogle Scholar
  10. 10.
    Kay J, Matteson EL, Dasgupta B et al (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58:964–975PubMedCrossRefGoogle Scholar
  11. 11.
    St Clair EW, Heijde DM van der, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443CrossRefGoogle Scholar
  12. 12.
    Emery P, Breedveld FC, Hall S et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375–382PubMedCrossRefGoogle Scholar
  13. 13.
    Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37PubMedCrossRefGoogle Scholar
  14. 14.
    Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210–221PubMedCrossRefGoogle Scholar
  15. 15.
    Krieckaert CL, Bartelds GM, Lems WF et al (2010) The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 12:217PubMedCrossRefGoogle Scholar
  16. 16.
    Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F et al (2011) Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90:359–371Google Scholar
  17. 17.
    Mackey AC, Green L, Liang LC et al (2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44:265–267Google Scholar
  18. 18.
    Listing J, Strangfeld A, Kekow J et al (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667–677PubMedCrossRefGoogle Scholar
  19. 19.
    Berthelot JM, De Bandt M, Goupille P et al (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76:28–34PubMedCrossRefGoogle Scholar
  20. 20.
    Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147PubMedGoogle Scholar
  21. 21.
    Alexander T, Klotz O, Feist E et al (2005) Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist. Ann Rheum Dis 64:1245–1246PubMedCrossRefGoogle Scholar
  22. 22.
    Naumann L, Feist E, Natusch A et al (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann Rheum Dis 69:466–467PubMedCrossRefGoogle Scholar
  23. 23.
    Gauldie J, Richards C, Harnish D et al (1987) Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 84:7251–7255CrossRefGoogle Scholar
  24. 24.
    Kavanaugh A (2012) Abstract 772, ACR-KongressGoogle Scholar
  25. 25.
    Burmester GR, Weinblatt ME, McInnes IB et al (2012) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis (im Druck). DOI 10.1136/annrheumdis-2012-202450Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Medizinische Klinik mit Schwerpunkt für Rheumatologie und klinische ImmunologieCharité – Universitätsmedizin Berlin, Campus MitteBerlinDeutschland

Personalised recommendations